The Christie NHS Foundation Trust
ESMO Fellowship Host Institute
|Contact person||Diane Byrne|
|Contact||Tel: +44 161 446 3683 - diane(dot)byrne(at)christie(dot)nhs(dot)uk|
|Web||The Christie NHS Foundation Trust|
- Clinical Research Fellowship
Training Experience Required
- Proficiency in written and spoken English.
- Licence to practise as a physician in the European Union.
- At least two years post-graduate training in Oncology.
The Christie NHS Foundation Trust is one of the largest cancer centres in Europe, treating more than 40,000 patients a year. It was the first centre in the UK to be officially accredited as a comprehensive cancer centre.
Clinical Oncology is the largest department in the hospital and its academic basis has been bolstered by the creation of the Radiation Related Research (RRR) Group of the MCRC (Manchester Cancer Research Centre), a thriving group that embraces clinical and basic radiobiology and radiotherapy. The RRR group was reviewed as one of the 3 centres of excellence for radiotherapy research within the UK.
The Neuro-oncology (CNS tumour) service operates across both The Christie and the regional neurosurgical centre at Salford Royal NHS Foundation Trust. There are separate, well-developed, highly-specialised Multi-disciplinary Team Meetings (MDTs) for Neurosciences (including primary and metastatic CNS tumours), Base of Skull tumours (including selection of patients for proton therapy), Pituitary tumours and patients with Neurofibromatosis Type II (NF2).
The Neuro-oncology service is well-staffed, with 5 consultant clinical oncologists, 4 sub-specialised consultant neuro-surgeons, 3 skull base surgeons, 1 endoscopic skull base surgeon, 2 ENT (Ear, nose & throat) surgeons, 2 neuro-pathologists, 4 sub-specialised neuro-radiologists, 1 neurologist, 3 clinical nurse specialists, 1 specialist radiographer, 2 Stereotactic Radiosurgery (SRS) radiographers, neuro-psychologists, neuro-oncology Allied Health Professionals and MDT co-ordinators.
The CNS disease group is highly research-active. The Christie is an EORTC Brain Tumour Group site, and supports a portfolio of phase I, II and III clinical trials. Systemic and novel agent clinical trials are led by Dr McBain, while Dr Whitfield is active in developing radiotherapy related research. There are close links with the University of Manchester Imaging Group, led by Professor Alan Jackson and based at the Wolfson Molecular Imaging Centre on the Christie site, and many of our patients participate in advanced MR or PET imaging studies. Neurocognitive functioning of brain tumour patients is increasingly recognised as a key research area, and we are working with Prof Montaldi’s group at University of Manchester to develop research in this area. The delivery of more complex treatments, and increased clinical trial participation, has meant that the activity of the CNS service has grown considerably over recent years and we run a dedicated weekly neuro-oncology research clinic.
We wish to appoint a Clinical Research Fellow in neuro-oncology, to focus on research into primary and metastatic CNS tumours. The post-holder will be helped in collaboration with Dr McBain, Dr Whitfield and Prof Montaldi to develop, and help to run and analyse a proposed study of neurocognitive functioning with MRI imaging correlates in low grade brain tumour patients. Funding for the necessary imaging has already been secured from Manchester University. In addition, the Fellow will continue the running of a novel PET imaging study in brain tumour patients developed by our current neuro-oncology Fellow, in collaboration with Prof Jackson. This study has started recruitment, and the Fellow will be involved in ongoing recruitment, analysis of imaging data, and writing of publications. He/she will also be involved in the weekly research clinic, giving excellent experience in the conduct of Phase I-III trials.
- Separate, highly specialised Multidisciplinary team (MDT) meetings for Neurosciences, Base of Skull, Pituitary, NF2 and supportive care.
- Dedicated weekly general neuro-oncology new patient clinic seeing 5-8 new cases per week from the Neurosciences MDT.
- Weekly neuro-oncology clinics in which new patients from the other MDTs are seen (skull base, pituitary, NF2), as well as follow-up of existing patients, with chemotherapy delivery and late effects.
- Dedicated weekly neuro-oncology research clinic supporting a portfolio of phase I, II and III clinical trials.
- Joint clinic with ENT (Ear, nose and throat) and base of skull surgeons for SRS for vestibular schwannomas.
- Dedicated brain metastases clinic.
- Full range of fractionated radiotherapy including IMRT, VMAT and SRS using the state-of-the-art Novalis Tx system with Exac-Trac imaging.
- Exposure to the North of England sub-specialist service managing NF2.